Novartis AG ADR (NVS)vsStrata Critical Medical, Inc. (SRTA)
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
SRTA
Strata Critical Medical, Inc.
$5.36
-7.51%
HEALTHCARE · Cap: $458.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 24652% more annual revenue ($56.58B vs $228.58M). NVS leads profitability with a 23.9% profit margin vs 20.6%. SRTA earns a higher WallStSmart Score of 51/100 (C-).
NVS
Hold49
out of 100
Grade: D+
SRTA
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Intrinsic value data unavailable for SRTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 87.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SRTA
The strongest argument for SRTA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 20.6% and operating margin at -2.8%. Revenue growth of 87.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SRTA
The primary concerns for SRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while SRTA is a growth play — different risk/reward profiles.
SRTA carries more volatility with a beta of 2.20 — expect wider price swings.
SRTA is growing revenue faster at 87.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SRTA scores higher overall (51/100 vs 49/100), backed by strong 20.6% margins and 87.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Strata Critical Medical, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?